The European Hematology Association Roadmap for European Hematology Research: a consensus document.
Détails
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_533802389170
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The European Hematology Association Roadmap for European Hematology Research: a consensus document.
Périodique
Haematologica
Contributeur⸱rice⸱s
EHA Roadmap for European Hematology Research, Engert A., Balduini C., Brand A., Coiffier B., Cordonnier C., Döhner H., de Wit TD. , Eichinger S., Fibbe W., Green T., de Haas F., Iolascon A., Jaffredo T., Rodeghiero F., Salles G., Schuringa JJ., André M., Andre-Schmutz I., Bacigalupo A., Bochud PY., Boer Md., Bonini C., Camaschella C., Cant A., Cappellini MD., Cazzola M., Celso CL., Dimopoulos M., Douay L., Dzierzak E., Einsele H., Ferreri A., De Franceschi L., Gaulard P., Gottgens B., Greinacher A., Greinacher A., Gresele P., Gribben J., de Haan G., Hansen JB., Hochhaus A., Kadir R., Kaveri S., Kouskoff V., Kühne T., Kyrle P., Ljungman P., Maschmeyer G., Méndez-Ferrer£££Simón£££ S. , Milsom M., Mummery C., Ossenkoppele G., Pecci A., Peyvandi F., Philipsen S., Reitsma P., Ribera JM., Risitano A., Rivella S., Ruf W., Schroeder T., Scully M., Socie G., Staal F., Stanworth S., Stauder R., Stilgenbauer S., Tamary H., Theilgaard-Mönch K., Thein SL., Tilly H., Trneny M., Vainchenker W., Vannucchi AM., Viscoli C., Vrielink H., Zaaijer H., Zanella A., Zolla L., Zwaginga JJ., Martinez PA., van den Akker E., Allard S., Anagnou N., Andolfo I., Andrau JC., Angelucci E., Anstee D., Aurer I., Avet-Loiseau H., Aydinok Y., Bakchoul T., Balduini A., Balduini C., Barcellini W., Baruch D., Baruchel A., Bayry J., Bento C., van den Berg A., Bernardi R., Bianchi P., Bigas A., Biondi A., Bohonek M., Bonnet D., Borchmann P., Borregaard N., Brækkan S., van den Brink M., Brodin E., Bullinger L., Buske C., Butzeck B., Cammenga J., Campo E., Carbone A., Cervantes F., Cesaro S., Charbord P., Claas F., Cohen H., Conard J., Coppo P., Corrons JL., Costa Ld., Davi F., Delwel R., Dianzani I., Domanović D., Donnelly P., Drnov?ek£££Tadeja Dovč£££ TD. , Dreyling M., Du MQ., Dufour C., Durand C., Efremov D., Eleftheriou A., Elion J., Emonts M., Engelhardt M., Ezine S., Falkenburg F., Favier R., Federico M., Fenaux P., Fitzgibbon J., Flygare J., Foà R., Forrester L., Galacteros F., Garagiola I., Gardiner C., Garraud O., van Geet C., Geiger H., Geissler J., Germing U., Ghevaert C., Girelli D., Godeau B., Gökbuget N., Goldschmidt H., Goodeve A., Graf T., Graziadei G., Griesshammer M., Gruel Y., Guilhot F., von Gunten S., Gyssens I., Halter J., Harrison C., Harteveld C., Hellström-Lindberg E., Hermine O., Higgs D., Hillmen P., Hirsch H., Hoskin P., Huls G., Inati A., Johnson P., Kattamis A., Kiefel V., Kleanthous M., Klump H., Krause D., Hovinga JK., Lacaud G., Lacroix-Desmazes S., Landman-Parker J., LeGouill S., Lenz G., von Lilienfeld-Toal M., von Lindern M., Lopez-Guillermo A., Lopriore E., Lozano M., MacIntyre E., Makris M., Makris M., Mannhalter C., Martens J., Mathas S., Matzdorff A., Medvinsky A., Menendez P., Migliaccio AR., Miharada K., Mikulska M., Minard V., Montalbán C., de Montalembert M., Montserrat E., Morange PE., Mountford J., Muckenthaler M., Müller-Tidow C., Mumford A., Nadel B., Navarro JT., Nemer We., Noizat-Pirenne F., O'Mahony B., Oldenburg J., Olsson M., Oostendorp R., Palumbo A., Passamonti F., Patient R., Peffault R., Pflumio F., Pierelli L., Piga A., Pollard D., Raaijmakers M., Radford J., Rambach R., Rao AK., Raslova H., Rebulla P., Rees D., Ribrag V., Rijneveld A., Rinalducci S., Robak T., Roberts I., Rodrigues C., Rosendaal F., Rosenwald A., Rule S., Russo R., Saglio G., Sanchez M., Scharf RE., Schlenke P., Semple J., Sierra J., So-Osman C., Soria JM., Stamatopoulos K., Stegmayr B., Stunnenberg H., Swinkels D., Barata£££João Pedro Taborda£££ JP. , Taghon T., Taher A., Terpos E., Thachil J., Tissot JD., Touw I., Toye A., Trappe R., Traverse-Glehen A., Unal S., Vaulont S., Viprakasit V., Vitolo U., van Wijk R., Wójtowicz A., Zeerleder S., Zieger B.
ISSN
1592-8721 (Electronic)
ISSN-L
0390-6078
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
101
Numéro
2
Pages
115-208
Langue
anglais
Résumé
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at euro23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap.The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders.The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
Pubmed
Web of science
Open Access
Oui
Création de la notice
05/08/2016 15:32
Dernière modification de la notice
20/08/2019 15:08
Données d'usage
